Constitutively active Akt contributes to vincristine resistance in human retinoblastoma cells

Cancer Investigation

Volumn 28, Issue 2, 2010, Pages 156-165

  Zhang, Hao ^a   Li, Bin ^a   Bai, Shu Wei ^a   Wang, Hui Juan ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Akt; Drug resistance; P glycoprotein; Retinoblastoma; Vincristine

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; PROTEIN KINASE B; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL DEATH; CELL STRAIN SO RB50; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PRIORITY JOURNAL; RETINOBLASTOMA;

CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; PROTO-ONCOGENE PROTEINS C-AKT; RETINAL NEOPLASMS; RETINOBLASTOMA; VINCRISTINE;

EID: 77149178406     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357900903179641     Document Type: Article

References (24)

1. Shields, C.L.; Shields, J.A. Basic understanding of current classification and management of retinoblastoma. Curr Opin Ophthalmol 2006, 17(3), 228-234.
2. Madhavan, J.; Ganesh, A.; Kumaramanickavel, G. Retinoblastoma: from disease to discovery. Ophthalmic Res 2008, 40(5), 221-226.
3. Takara, K.; Sakaeda, T.; Okumura, K. An update on overcomingMDR1- mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des 2006, 12(3), 273-286.
4. Redmond, K.M.; Wilson, T.R.; Johnston, P.G.; Longley, D.B. Resistance mechanisms to cancer chemotherapy. Front Biosci 2008, 13, 5138-5154.
5. Filho, J.P.; Correa, Z.M.; Odashiro, A.N.; Coutinho, A.B.; Martins, M.C.; Erwenne, C.M.; Burnier, M.N., Jr. Histopathological features and P-glycoprotein expression in retinoblastoma. Invest Ophthalmol Vis Sci 2005, 46(10), 3478-3483.
6. Souza Filho, J.P.;Martins,M.C.; Caissie, A.L.; Torres, V.L.; Fernandes L.H.; Erwenne, C.M.; Burnier, M.N., Jr. Relationship between histopathological features of chemotherapy treated retinoblastoma and P-glycoprotein expression. Clin Experiment Ophthalmol 2005, 33(3), 279-284.
7. Prabhudesai, S.G.; Rekhraj, S.; Roberts, G.; Darzi, A.W.; Ziprin, P. Apoptosis and chemo-resistance in colorectal cancer. J Surg Oncol 2007, 96(1), 77-88.
8. McKenzie, S.; Kyprianou, N. Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance. J Cell Biochem 2006, 97(1), 18-32.
9. Hennessy, B.T.; Smith, D.L.; Ram, P.T.; Lu, Y.;Mills, G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005, 4(12), 988-1004.
10. Gu, P.; Su, Y.; Guo, S.; Teng, L.; Xu, Y.; Qi, J.; Gong, H.; Cai, Y. Over-expression of COX-2 induces human ovarian cancer cells (CAOV-3) viability, migration and proliferation in association with PI3-k/Akt activation. Cancer Invest 2008, 26(8), 822-829.
11. Hovelmann, S.; Beckers, T.L.; Schmidt, M. Molecular alterations in apoptotic pathways after PKB/Akt-mediated chemoresistance in NCI H460 cells. Br J Cancer 2004, 90(12), 2370-2377.
12. Kim, S.H.; Juhnn, Y.S.; Song, Y.S. Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells. Ann N Y Acad Sci 2007, 1095, 82-89.
13. Chakraborty, S.; Khare, S.; Dorairaj, S.K.; Prabhakaran, V.C.; Prakash, D.R.; Kumar, A. Identification of genes associated with tumorigenesis of retinoblastoma bymicroarray analysis. Genomics 2007, 90(3), 344-353. (Pubitemid 47176334)
14. Rodriguez-Galindo, C.; Wilson, M.W.; Haik, B.G.; Merchant, T.E.; Billups, C.A.; Shah, N.; Cain, A.; Langston, J.; Lipson, M.; Kun, L.E.; Pratt, C.B. Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol 2003, 21(10), 2019-2025.
15. Fahy, B.N.; Schlieman, M.G.; Virudachalam, S.; Bold, R.J. Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer. J Am Coll Surg 2004, 198(4), 591-599.
16. VanderWeele, D.J.; Zhou, R.; Rudin, C.M. Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Mol Cancer Ther 2004, 3(12), 1605-1613.
17. Lee, S.; Choi, E.J.; Jin, C.; Kim, D.H. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 2005, 97(1), 26-34.
18. Sellers, W.R.; Kaelin, W.G., Jr. Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol 1997, 15(11), 3301-3312.
19. Wikman, H.; Kettunen, E. Regulation of the G1/S phase of the cell cycle and alterations in the RB pathway in human lung cancer. Expert Rev Anticancer Ther 2006, 6(4), 515-530.
20. Palmero, I.; Peters, G. Perturbation of cell cycle regulators in human cancer. Cancer Surv 1996, 27, 351-367.
21. Corson, T.W.; Gallie, B.L. One hit, two hits, three hits, more Genomic changes in the development of retinoblastoma. Genes Chromosomes Cancer 2007, 46(7), 617-634.
22. Roy, K.R.; Arunasree, K.M.; Dhoot, A.; Aparna, R.; Reddy, G.V.; Vali, S.; Reddanna, P. C-Phycocyanin inhibits 2- acetylaminofluorene-induced expression of MDR1 in mouse macrophage cells: ROS mediated pathway determined via combination of experimental and In silico analysis. Arch Biochem Biophys 2007, 459(2), 169-177.
23. Chiarini, F.; Del Sole, M.; Mongiorgi, S.; Gaboardi, G.C.; Cappellini, A.; Mantovani, I.; Follo, M.Y.; McCubrey, J.A.; Martelli, A.M. The novel Akt inhibitor, perifosine, induces caspasedependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia 2008, 22(6), 1106-1116.
24. Barancik, M.; Bohacova, V.; Sedlak, J.; Sulov́ a, Z.; Breier, A. LY294002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci 2006, 29(5), 426-434.